Viewing data from:

CLINDAMYCIN PHOSPHATE AND TRETINOIN

ANDA

CLINDAMYCIN PHOSPHATE; TRETINOIN | A202564 | ACTAVIS MID ATLANTIC LLC

1 strength0 unique patents0 unique exclusivities

Reference Listed Drug: ZIANA(TE code: AB1)

Hatch-Waxman Litigation

1 case on OB patents from PACER

Case	Court	Filed	Status	Judge
Medicis Pharmaceutical Corporation et al v. Actavis Mid Atlantic LLC 1:2011cv00409 2 patentsANDA 202564Clindamycin phosphate and tretinoin	D. Del.	2011-05-11	Terminated 2013-04-12	—

Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 2 NDCs

Highest NADAC/Unit

$4.90

per gm

Lowest NADAC/Unit

$3.58

per gm

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
00472179030CLINDA-TRETINOIN 1.2%-0.025%	$4.90	GM	Generic	—	2026-06-17
00472179060CLINDA-TRETINOIN 1.2%-0.025%	$3.58	GM	Generic	—	2026-06-17

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

VA Federal Supply Schedule

Government-negotiated contract prices | 2 NDCs (2 FSS)

Lowest Price

$124.74

Highest Price

$225.33

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
00472-1790-30CLINDAMYCIN PHOSPHATE 1.2%/TRETINOIN 0.025% G	$124.74	FSS	AvKare, LLC	06/14/2028
00472-1790-60CLINDAMYCIN PHOSPHATE 1.2%/TRETINOIN 0.025% G	$225.33	FSS	AvKare, LLC	06/14/2028

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Jun 16, 2015	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — 1.2%;0.025%

AB1

0 patents0 exclusivities▴

GEL;TOPICAL | Approved: Jun 12, 2015

No patent or exclusivity listings for this strength.